Post-Transplant Cyclophosphamide and Urinary-Derived Human Chorionic Gonadotropin and Epidermal Growth Factor (uhCG/EGF) As Graft Versus Host Disease Prophylaxis for Mismatched Unrelated Donor Transplantation: A Phase I Dose Escalation Study (PTCY2HCG3)
Key Points
Prophylaxis with uhCG and EGF shows promise in managing graft versus host disease.
The trial involved a dose escalation approach focusing on safety and tolerability.
Key metrics include the assessment of graft acceptance and side effects among participants.
Early outcomes indicate a need for further investigation into this combined therapeutic strategy.
Like
Bookmark
Share
Like
Bookmark
Share
Post-Transplant Cyclophosphamide and Urinary-Derived Human Chorionic Gonadotropin and Epidermal Growth Factor (uhCG/EGF) As Graft Versus Host Disease Prophylaxis for Mismatched Unrelated Donor Transplantation: A Phase I Dose Escalation Study (PTCY2HCG3) | Synapse